Sanofi expands insulin access with $35 monthly cap for all Americans

MORRISTOWN, N.J. - Sanofi US, part of the $110 billion healthcare giant Sanofi, announced Friday it will expand its Insulins Valyou Savings Program to offer a 30-day supply of any Sanofi insulin for $35 to all patients in the United States with a valid prescription, regardless of insurance status. The company, which maintains impressive gross profit margins of over 71%, continues to balance profitability with healthcare accessibility.

The expanded program, which takes effect January 1, 2026, will include patients with commercial insurance and Medicare coverage, removing the previous limitation that restricted the program to uninsured individuals. According to InvestingPro analysis, Sanofi’s strong financial health score and robust revenue of $53.87 billion position it well to support such initiatives while maintaining shareholder value.

"No one should struggle to afford their insulin," said Adam Gluck, Head of US Corporate Affairs at Sanofi, in a press release statement. Gluck noted the initiative builds on an idea "first championed by President Trump to lower costs for American patients at the pharmacy counter."

The program will cover all Sanofi insulin products and will be available at most pharmacies across the country, including independent and rural locations. Patients can purchase any combination, type, and quantity of Sanofi insulins with a valid prescription for the fixed monthly price.

Olivier Bogillot, Head of General Medicines, North America at Sanofi, emphasized that financial barriers can lead to insulin rationing or skipped doses, which can have serious health consequences for diabetes patients.

The company stated the program works without creating "complex hurdles for patients" and will be implemented nationwide as part of Sanofi’s efforts to improve medication access and affordability.

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY. The stock currently offers an attractive dividend yield of 3.55% and appears undervalued according to InvestingPro Fair Value metrics. Investors can access detailed analysis and 12+ additional ProTips about Sanofi’s financial outlook through InvestingPro’s comprehensive research reports, available for over 1,400 US-listed companies.

In other recent news, Sanofi has been the subject of several notable analyst actions. Morgan Stanley upgraded Sanofi’s stock rating from Equalweight to Overweight, citing a positive growth outlook. The firm also increased its price target for Sanofi to $58.00, expressing confidence in the company’s potential for organic growth and margin improvement. Meanwhile, Jefferies reiterated its Buy rating on Sanofi, maintaining a price target of EUR120.00. Jefferies emphasized the safety profile of Sanofi’s OX40L-targeting treatment, noting its potential advantage over Amgen’s comparable treatment by avoiding T-cell depletion and related side effects. These recent developments highlight the positive sentiment among analysts regarding Sanofi’s growth prospects and product safety.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.